An update on short-course episodic and prevention therapies for herpes genitalis

Herpes

Volumn 14, Issue SUPPL. 1, 2007, Pages

  Corey, Lawrence ^a   Bodsworth, Neil ^b   Mindel, Adrian ^c,d   Patel, Raj ^e   Schacker, Timothy ^f   Stanberry, Lawrence ^g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Taylor Square Private Clinic ^*  (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Chemotherapy; Episodic therapy; Herpes genitalis; Immunomodulation; Prevention; Reactivation; Short course therapy; Suppressive therapy; Vaccine; Viral shedding

Indexed keywords

ACICLOVIR; ALUMINUM POTASSIUM SULFATE; ANTIVIRUS AGENT; CARBOPOL 974P; COMBOGEL; FAMCICLOVIR; GANGLIOSIDE GD2; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 VACCINE; MICROBICIDE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; VALACICLOVIR; VIVAGEL;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PRIORITY JOURNAL; PSYCHOSEXUAL DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; PRACTICE GUIDELINES; RECURRENCE; VIRUS SHEDDING;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 34547776391     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Lafferty WE, Coombs RW, Benedetti T, Critchlow C, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987;316:1444-1449.
2. Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. J Infect Dis 2002;186:S34-S39.
3. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603.
4. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998;101:1500-1508.
5. Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci USA 1997;94:10289-10294.
6. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis 2002;34:958-962.
7. Strand A, Patel R, Wulf HC, Coates KM; International Valaciclovir HSV Study Group. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex Transm Infect 2002;78:435-439.
8. Wald A, Carrell D, Remington M, Kexel E, Zeh J. Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002;34:944-948.
9. Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2006;42:8-13.
10. Bloch MT, Heley S, Agnew J, on behalf of the FaST study group. Short-course famciclovir as episodic treatment of recurrent genital herpes - results of the FaST study. IHMF® Annual Meeting Abstracts. Herpes 2006;13:47A.
11. Patel R, Tyring S, Strand A, Price MJ, Grant DM. Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection. Sex Transm Infect 1999;75:398-402.
12. Romanowski B, Marina RB, Roberts JN; Valtrex HS230017 Study Group. Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003;30:226-231.
13. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.
14. Wald A, Selke S, Warren T, Aoki FY, Sacks S, Diaz-Mitoma F et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33:529-533.
15. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998;178:1642-1648.
16. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997;176:766-770.
17. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002;186:1718-1725.
18. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185:45-52.
19. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153.
20. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-66.
21. Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to Antimicrobial Therapy 2006, 36th edn. Sperryville, VA: Antimicrobial Therapy Inc., 2006.
22. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998;178:349-359.
23. Schacker T, Hu HL, Koelle DM, Zeh J, Saltzman R, Boon R et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-28.
24. Romanowski B, Aoki FY, Martel AY, Lavender EA, Parsons JE, Saltzman RL. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. AIDS 2000;14:1211-1217.
25. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003;188:1009-1016.
26. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004;190:693-696.
27. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998;178:1616- 1622.
28. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347:1652-1661.